Palisade Bio Dividend Yield

What does Palisade Bio do? Palisade Bio, Inc. develops oral therapies for gastrointestinal complications caused by post-operative digestive enzyme damage. The company focuses on LB1148, an oral liquid formulation containing tranexamic acid (TXA), polyethylene glycol, carbohydrates, and electrolytes, designed to prevent enzyme leakage into the peritoneal cavity during high-risk surgeries. LB1148 is administered before surgeries to protect the intestinal epithelial barrier. The company's lead product targets acute and chronic conditions resulting from digestive enzyme damage, with no other products or revenue streams mentioned. Palisade Bio, Inc. is a biopharmaceutical company headquartered in Carlsbad, California, employing 12 full-time employees. It went public via IPO on December 20, 2006, but does not generate revenue from product sales as it is in the development phase. The company's business model relies on developing therapies like LB1148 for surgical patients, with no indication of partnerships, licensing deals, or other revenue sources beyond potential future product sales after regulatory approval. The lead therapeutic candidate LB1148 is formulated as an aqueous solution for oral (enteral) administration. The company's approach is based on the discovery that intestinal epithelial barrier damage leads to digestive enzyme leakage, causing tissue damage and inflammation. No other products, brands, or revenue streams are referenced in the business description, and the company does not sell any products at this stage. Palisade Bio is one of the most popular companies on Eulerpool.